News Archives

PsiOxus Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev

PsiOxus Therapeutics raises a £25m Series C investment to progress oncolytic virus plus checkpoint inhibitor combination study in metastatic colorectal cancer

PsiOxus Therapeutics to present promising new data on novel oncolytic immunoncology platform at AACR 2015

PsiOxus Therapeutics expands clinical studies for immuno-oncolytic treatment following positive response to intravenous delivery

EMA grants positive opinion for orphan drug status for ovarian cancer oncolytic vaccine